Solesta, an injectable gel delivered into the anal canal in an outpatient procedure, is a minimally invasive treatment option.
The FDA previously noted difficulties in treating fecal incontinence.
Related Articles on Incontinence:
FDA Approves Solesta to Treat Life-Altering Fecal Incontinence
FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product
USC Colorectal Surgeon Andreas Kaiser Named GI Journal Editor
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
